Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irbesartan plus trichlormethiazide in essential hypertension: blood pressure and uric acid effects
jRCT1090220183Completed
- Sponsor
- Nagoya Medical Association
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of irbesartan and Trichlormethiazide in essential hypertension and hyperuricemia, sponsored by Nagoya Medical Association. Primary endpoint: Percent change in blood pressure from baseline to 12 weeks. Started Jun 2014; status: completed.
02
Drugs
irbesartanTrichlormethiazide
03
Conditions
essential hypertensionhyperuricemia
Beyond the preview
Go deeper on jRCT1090220183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1090220183.